Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2014; 5(4): 677-692
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.677
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.677
Cyclooxygenase-2 and the inflammogenesis of breast cancer
Randall E Harris, Bruce C Casto, Zachary M Harris, The Ohio State University Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH 43210-1351, United States
Randall E Harris, College of Medicine and College of Public Health, Center of Molecular Epidemiology and Environmental Health, The Ohio State University Medical Center, Columbus, OH 43210-1351, United States
Author contributions: Harris RE directed the research and wrote the initial manuscript; Casto BC and Harris ZM assisted in interpretation of data, development of the final model of mammary carcinogenesis and revision of the manuscript.
Correspondence to: Randall E Harris, MD, PhD, Professor, College of Medicine and College of Public Health, Center of Molecular Epidemiology and Environmental Health, The Ohio State University Medical Center, 1841 Neil Avenue, Columbus, OH 43210-1351, United States. Harris.44@osu.edu
Telephone: +1-614-2924720 Fax: +1-614-6883533
Received: January 12, 2014
Revised: March 7, 2014
Accepted: March 13, 2014
Published online: October 10, 2014
Revised: March 7, 2014
Accepted: March 13, 2014
Published online: October 10, 2014
Core Tip
Core tip: Mammary carcinogenesis often evolves as a series of highly specific cellular and molecular changes in response to induction of constitutive over-expression of cyclooxygenase-2 (COX-2) and the prostaglandin cascade; reciprocally, agents that block COX-2 have significant value in the chemoprevention and therapy of breast cancer.